N-Zyme Biomedical develops pepsin inhibitor therapies and drug formulations for reflux diseases such as LPR and GERD.
N-Zyme Biomedical has raised $2.8M in total funding. The most recent round was Grant. The last funding was announced in September 2026.
N-Zyme Biomedical's investors include National Institute on Aging.
N-Zyme Biomedical is headquartered in Milwaukee, United States.
N-Zyme Biomedical develops pepsin inhibitor therapies and drug formulations for reflux diseases such as LPR and GERD.
N-Zyme Biomedical is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"N-Zyme Biomedical — Funding & Investors." VCBacked, September 22, 2026, https://www.vcbacked.co/company/n-zyme-biomedical. Accessed October 2, 2026.
VCBacked. (2026). N-Zyme Biomedical — Funding & Investors. Retrieved October 2, 2026, from https://www.vcbacked.co/company/n-zyme-biomedical
{{cite web |title=N-Zyme Biomedical — Funding & Investors |url=https://www.vcbacked.co/company/n-zyme-biomedical |website=VCBacked |access-date=October 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated